Clinical Trial Update: Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

View source ↗

Summary

Update on prognosis for patients with aggressive B-cell lymphoma treated with a rituximab-containing anthracycline regimen, based on completed trial data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Rituxan (rituximab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: B-Cell Lymphomas | Status: COMPLETED